CompletedPhase 3NCT00265941
Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With Stage III or Stage IV Head and Neck Cancer
Studying Squamous cell carcinoma of the hypopharynx
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Radiation Therapy Oncology Group
- Principal Investigator
- David Rosenthal, MD, MDM.D. Anderson Cancer Center
- Intervention
- cetuximab(drug)
- Enrollment
- 940 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2005 – 2022
Study locations (30)
- Lurleen Wallace Comprehensive Cancer at University of Alabama - Birmingham, Birmingham, Alabama, United States
- Providence Cancer Center, Anchorage, Alaska, United States
- Mayo Clinic Scottsdale, Scottsdale, Arizona, United States
- Arkansas Cancer Research Center at University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
- Auburn Radiation Oncology, Auburn, California, United States
- Alta Bates Summit Comprehensive Cancer Center, Berkeley, California, United States
- Peninsula Medical Center, Burlingame, California, United States
- Radiation Oncology Centers - Cameron Park, Cameron Park, California, United States
- Mercy Cancer Center at Mercy San Juan Medical Center, Carmichael, California, United States
- East Bay Radiation Oncology Center, Castro Valley, California, United States
- Valley Medical Oncology Consultants - Castro Valley, Castro Valley, California, United States
- Cancer Care Center at John Muir Health - Concord Campus, Concord, California, United States
- City of Hope Comprehensive Cancer Center, Duarte, California, United States
- Valley Medical Oncology, Fremont, California, United States
- Virginia K. Crosson Cancer Center at St. Jude Medical Center, Fullerton, California, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
National Cancer Institute (NCI) · NRG Oncology
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00265941 on ClinicalTrials.govOther trials for Squamous cell carcinoma of the hypopharynx
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07063212A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)Memorial Sloan Kettering Cancer Center
- RECRUITINGPHASE1NCT06761937Thermoradiotherapy for Locally Advanced Head and Neck Cancer PatientsErasmus Medical Center
- RECRUITINGPHASE3NCT06706401Lymphocyte-Sparing And Radio-Immunotherapy in Head and Neck CarcinomaCentre Leon Berard
- RECRUITINGNCT06380686Head and Neck Carcinoma Clinical Research Platform for Molecular and Blood-based Biomarkers, Treatment and OutcomeAIO-Studien-gGmbH
- RECRUITINGPHASE3NCT06525220A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)Merus B.V.
- RECRUITINGPHASE3NCT05333523Personalized Elective Neck Irradiation Guided by Sentinel Lymph Node Biopsy in Larynx and Pharynx Cancer. The PRIMO Study.Radboud University Medical Center
- RECRUITINGPHASE2NCT04858269First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma PatientsWake Forest University Health Sciences
- ACTIVE NOT RECRUITINGPHASE3NCT04590963Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck CancerAstraZeneca
See all trials for Squamous cell carcinoma of the hypopharynx →